Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Terns Pharmaceuticals Inc (NQ: TERN )

5.738 +0.298 (+5.49%)
Streaming Delayed Price Updated: 11:46 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Terns Pharmaceuticals Inc

< Previous 1 2 Next >
Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Announces Pricing of $75 Million Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit
Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemia 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.